Immunity to SARS-CoV-2 variants of concern
- PMID: 33707254
- DOI: 10.1126/science.abg7404
Immunity to SARS-CoV-2 variants of concern
Comment on
-
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.Science. 2021 Mar 12;371(6534):1152-1153. doi: 10.1126/science.abg6105. Epub 2021 Jan 29. Science. 2021. PMID: 33514629 Free PMC article.
Similar articles
-
Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.Microbiol Spectr. 2023 Jun 15;11(3):e0516322. doi: 10.1128/spectrum.05163-22. Epub 2023 Apr 26. Microbiol Spectr. 2023. PMID: 37098903 Free PMC article.
-
Role of COVID-19 Vaccines in SARS-CoV-2 Variants.Front Immunol. 2022 May 20;13:898192. doi: 10.3389/fimmu.2022.898192. eCollection 2022. Front Immunol. 2022. PMID: 35669787 Free PMC article. Review.
-
Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.J Allergy Clin Immunol. 2022 Apr;149(4):1242-1252.e12. doi: 10.1016/j.jaci.2022.01.013. Epub 2022 Jan 29. J Allergy Clin Immunol. 2022. PMID: 35093484 Free PMC article.
-
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review.Clin Microbiol Infect. 2022 Feb;28(2):202-221. doi: 10.1016/j.cmi.2021.10.005. Epub 2021 Oct 27. Clin Microbiol Infect. 2022. PMID: 34715347 Free PMC article. Review.
-
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.JAMA. 2021 Jun 15;325(23):2370-2380. doi: 10.1001/jama.2021.7563. JAMA. 2021. PMID: 33983379 Free PMC article.
Cited by
-
A high-fidelity DNAzyme-assisted CRISPR/Cas13a system with single-nucleotide resolved specificity.Chem Sci. 2024 Apr 2;15(18):6934-6942. doi: 10.1039/d4sc01501k. eCollection 2024 May 8. Chem Sci. 2024. PMID: 38725495 Free PMC article.
-
Mucosal Vaccination with a Newcastle Disease Virus-Vectored Vaccine Reduces Viral Loads in SARS-CoV-2-Infected Cynomolgus Macaques.Vaccines (Basel). 2024 Apr 10;12(4):404. doi: 10.3390/vaccines12040404. Vaccines (Basel). 2024. PMID: 38675786 Free PMC article.
-
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.Cochrane Database Syst Rev. 2024 Apr 10;4(4):CD015112. doi: 10.1002/14651858.CD015112.pub3. Cochrane Database Syst Rev. 2024. PMID: 38597249
-
Human surfactant protein A inhibits SARS-CoV-2 infectivity and alleviates lung injury in a mouse infection model.Front Immunol. 2024 Mar 26;15:1370511. doi: 10.3389/fimmu.2024.1370511. eCollection 2024. Front Immunol. 2024. PMID: 38596675 Free PMC article.
-
Immunodominant conserved moieties on spike protein of SARS-CoV-2 renders virulence factor for the design of epitope-based peptide vaccines.Virusdisease. 2023 Dec;34(4):456-482. doi: 10.1007/s13337-023-00852-9. Epub 2023 Nov 23. Virusdisease. 2023. PMID: 38046066
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous